Association Between Prolactinoma and Body Mass Index

被引:18
作者
Al Sabie, Farah [1 ]
Tariq, Zunera [2 ]
Erickson, Dana [3 ]
Donegan, Diane [1 ,3 ]
机构
[1] Indiana Univ, Sch Med, Div Endocrinol Diabet & Metab, Indianapolis, IN USA
[2] Indiana Univ, Sch Med, Dept Internal Med, Indianapolis, IN USA
[3] Mayo Clin, Div Endocrinol Diabet & Metab, Rochester, MN USA
关键词
prolactinoma; hyperprolactinemia; obesity; BMI; WEIGHT-GAIN; FOOD-INTAKE; CABERGOLINE; OBESITY; HYPERPROLACTINEMIA; PREVALENCE; HORMONE; INSULIN; LEPTIN; WOMEN;
D O I
10.1016/j.eprac.2020.09.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Obesity is increasing worldwide, and certain endocrine disorders may contribute to weight gain. While several studies have examined the association between weight gain and prolactinomas, the results are conflicting. Therefore, this study aimed to determine if body mass index (BMI) is higher among those with prolactinomas than those without. Methods: We identified patients >= 18 years of age referred to an endocrine clinic between 2008 and 2018 with newly diagnosed prolactinomas. We extracted the relevant information, and comparative data was obtained from the 2015-2016 National Health and Nutrition Examination Survey. Results: In total, 34 cases met the inclusion criteria. One third of the patients described weight gain at presentation. Those with prolactinomas had a significantly higher BMI than the National Health and Nutrition Examination Survey population (median BMI, 29.8 kg/m(2) vs 28.3 kg/m(2), P = .0048). When stratified by sex, only men with prolactinomas had an increased BMI compared with the controls. Moreover, those with prolactinomas had a higher prevalence of class II obesity (BMI >= 35 kg/m(2)) than the survey population (35% vs 18%, P = .01). Among the prolactinoma patients, a correlation was observed between BMI and log-transformed prolactin levels (R-2 = 0.4, P = .0002). Conclusion: Weight gain can be a presenting symptom for patients with newly diagnosed prolactinomas. Those with prolactinomas have a higher BMI and an increased prevalence of class II obesity. These findings suggest that patients should be counseled regarding weight issues related to prolactinomas at presentation and should be a consideration in the investigative and treatment algorithm of prolactinomas. (C) 2020 AACE. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:312 / 317
页数:6
相关论文
共 26 条
[1]   Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia [J].
Atmaca, Aysegul ;
Bilgici, Birsen ;
Ecemis, Gulcin Cengiz ;
Tuncel, Ozgur Korhan .
ENDOCRINE, 2013, 44 (03) :756-761
[2]   BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants [J].
Aune, Dagfinn ;
Sen, Abhijit ;
Prasad, Manya ;
Norat, Teresa ;
Janszky, Imre ;
Tonstad, Serena ;
Romundstad, Pal ;
Vatten, Lars J. .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 353
[3]   Body weight gain after administration of antipsychotic drugs:: Correlation with leptin, insulin and reproductive hormones [J].
Baptista, T ;
Lacruz, A ;
de Mendoza, S ;
Guillén, JMM ;
Silvera, R ;
Angeles, F ;
Mendoza, MT ;
Hernández, L .
PHARMACOPSYCHIATRY, 2000, 33 (03) :81-88
[4]   Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis [J].
Byberg, Sarah ;
Futtrup, Jesper ;
Andreassen, Mikkel ;
Krogh, Jesper .
ENDOCRINE CONNECTIONS, 2019, 8 (10) :1395-1404
[5]   Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects [J].
Cincotta, AH ;
Meier, AH .
DIABETES CARE, 1996, 19 (06) :667-670
[6]   Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels [J].
Ciresi, Alessandro ;
Amato, Marco Calogero ;
Guarnotta, Valentina ;
Lo Castro, Flavia ;
Giordano, Carla .
CLINICAL ENDOCRINOLOGY, 2013, 79 (06) :845-852
[7]   Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia [J].
Colao, A ;
Di Sarno, A ;
Cappabianca, P ;
Briganti, F ;
Pivonello, R ;
Di Somma, C ;
Faggiano, A ;
Biondi, B ;
Lombardi, G .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 148 (03) :325-331
[8]   PROLACTINOMA AND BODY-WEIGHT - A RETROSPECTIVE STUDY [J].
CREEMERS, LB ;
ZELISSEN, PMJ ;
VANTVERLAAT, JW ;
KOPPESCHAAR, HPF .
ACTA ENDOCRINOLOGICA, 1991, 125 (04) :392-396
[9]   Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth [J].
Delgrange, Etienne ;
Vasiljevic, Alexandre ;
Wierinckx, Anne ;
Francois, Patrick ;
Jouanneau, Emmanuel ;
Raverot, Gerald ;
Trouillas, Jacqueline .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (06) :791-801
[10]   Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma [J].
Delibasi, Tuncay ;
Arslan, Muyesser Sayki ;
Cakal, Erman ;
Sahin, Mustafa ;
Topaloglu, Oya ;
Tutal, Esra ;
Unsal, Ilknur Ozturk ;
Karbek, Basak ;
Ucan, Bekir ;
Gungunes, Askin ;
Karakose, Melia ;
Caliskan, Mustafa ;
Demirci, Taner ;
Tabur, Gulfer ;
Ozbek, Mustafa .
JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2015, 16 (02) :86-90